A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (MONA)

Amgen

Status and phase: Completed; Phase 2

Conditions: Asthma

Treatments: Drug: Lodotra; Drug: Cortancyl

Study type: Interventional

Funder types: Industry

Identifiers

NCT00686335

NP01-201

EudraCT-Number: 2007-007316-29

Details and patient eligibility

About

The purpose of the study is to evaluate in subjects suffering from nocturnal asthma, the efficacy and safety of modified release Prednisone on signs and symptoms.

Full description

Study with completed results acquired from Horizon in 2024.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The subject must be able to understand the terms of the written informed consent form, and must provide a dated and signed form before the start of any study procedure
• At least 18 years old
• Patient having a diagnosis of asthma dating back more than 6 months at the time of inclusion
• Asthma necessitating a continuous treatment by oral corticoids
• A minimum of 3 nocturnal awakenings due to asthma during the last screening week
• Stable dose of oral glucocorticoids for at least 4 weeks prior to inclusion into the study
• No change in asthma medication during the last 4 weeks prior to V0
• Non-smoker or ex-smoker (having stopped smoking more than one year previously and with a smoking history of less than 10 pack years )
• Female patients of childbearing potential must be using a medically accepted contraceptive regimen
• Able to perform the required study procedures including handling of medication containers and diaries

Exclusion criteria

• Poorly controlled asthma, defined as meeting at least one of the following within the 4 weeks prior to Visit V0:

  • hospital admission for asthma (including treatment in an emergency room),
  • a lower airway infection,

• Diagnosis of chronic obstructive pulmonary disease or other relevant lung diseases (e.g. history of bronchiectasis, cystic fibrosis, bronchiolitis, lung resection, lung cancer, active tuberculosis, interstitial lung disease)

• Clinically significant abnormalities of the hematological or biochemical constants

• Pregnancy or breastfeeding

• Participation in another clinical study within 30 days preceding Visit V0,

• Re-entry of patients previously enrolled in this trial,

• Suspected inability or unwillingness to comply with the study procedures

• Alcohol or drug abuse

• Need to take a non-authorised concomitant treatment (cf. list of medicaments not authorised during the study) in the course of the study

• Other disease requiring treatment with corticosteroids

• Subject is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

• Patient with a hospitalisation scheduled during the study period

• Any uncontrolled concomitant disease requiring further clinical evaluation (e.g. uncontrolled diabetes, uncontrolled hypertension, etc.)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 2 patient groups

Lodotra

Experimental group

Description:

After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.

Treatment:

Drug: Lodotra

Cortancyl

Active Comparator group

Description:

During the 4 week run-in period, patients remained on their respective pre-study dose of prednisone or equivalent. However, patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl). Patients were to take their tablets with or after the morning meal (at 8am +/- 30 minutes) for 4 weeks.

Treatment:

Drug: Cortancyl